Tourmaline Bio (TRML) Competitors $19.68 -0.22 (-1.11%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$19.68 +0.00 (+0.03%) As of 06/13/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRML vs. IDYA, BLTE, SDGR, INDV, GLPG, APGE, BEAM, IMCR, TARS, and BHCShould you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Schrödinger (SDGR), Indivior (INDV), Galapagos (GLPG), Apogee Therapeutics (APGE), Beam Therapeutics (BEAM), Immunocore (IMCR), Tarsus Pharmaceuticals (TARS), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. Tourmaline Bio vs. Its Competitors IDEAYA Biosciences Belite Bio Schrödinger Indivior Galapagos Apogee Therapeutics Beam Therapeutics Immunocore Tarsus Pharmaceuticals Bausch Health Companies Tourmaline Bio (NASDAQ:TRML) and IDEAYA Biosciences (NASDAQ:IDYA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations. Does the MarketBeat Community prefer TRML or IDYA? IDEAYA Biosciences received 119 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 96.00% of users gave Tourmaline Bio an outperform vote while only 71.86% of users gave IDEAYA Biosciences an outperform vote. CompanyUnderperformOutperformTourmaline BioOutperform Votes2496.00% Underperform Votes14.00%IDEAYA BiosciencesOutperform Votes14371.86% Underperform Votes5628.14% Is TRML or IDYA more profitable? Tourmaline Bio's return on equity of -20.97% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -20.97% -20.56% IDEAYA Biosciences N/A -26.74%-25.54% Do analysts rate TRML or IDYA? Tourmaline Bio currently has a consensus target price of $49.33, indicating a potential upside of 150.68%. IDEAYA Biosciences has a consensus target price of $54.27, indicating a potential upside of 144.69%. Given Tourmaline Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Tourmaline Bio is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.93 Does the media prefer TRML or IDYA? In the previous week, IDEAYA Biosciences had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 6 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 1.49 beat IDEAYA Biosciences' score of 0.98 indicating that Tourmaline Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of TRML or IDYA? 91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 13.0% of Tourmaline Bio shares are owned by company insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, TRML or IDYA? Tourmaline Bio has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$42.12M-$3.21-6.13IDEAYA Biosciences$7M277.51-$274.48M-$3.59-6.18 Which has more volatility & risk, TRML or IDYA? Tourmaline Bio has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. SummaryTourmaline Bio beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks. Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRML vs. The Competition Export to ExcelMetricTourmaline BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$505.48M$3.09B$5.57B$8.50BDividend YieldN/A1.56%5.27%4.17%P/E Ratio-6.9832.6326.7519.66Price / SalesN/A455.18403.98152.07Price / CashN/A168.6838.2534.64Price / Book1.953.366.964.59Net Income-$42.12M-$72.35M$3.23B$248.23M7 Day Performance2.13%0.36%-1.22%-1.07%1 Month Performance26.80%16.10%6.34%2.59%1 Year Performance16.04%-15.37%33.05%13.50% Tourmaline Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRMLTourmaline Bio2.8437 of 5 stars$19.68-1.1%$49.33+150.7%+16.0%$505.48MN/A-6.9844Positive NewsAnalyst RevisionGap DownIDYAIDEAYA Biosciences3.8462 of 5 stars$21.71-0.1%$54.27+150.0%-41.8%$1.90B$7M-6.5880Analyst RevisionGap DownBLTEBelite Bio2.6241 of 5 stars$61.40+2.9%$96.67+57.4%+19.2%$1.90BN/A-55.3110Short Interest ↑Analyst RevisionSDGRSchrödinger2.4778 of 5 stars$25.47+3.5%$32.80+28.8%+3.9%$1.87B$230.49M-10.88790Gap DownINDVIndivior2.5666 of 5 stars$13.43-4.5%$15.00+11.7%-16.0%$1.85B$1.17B-38.371,164Positive NewsGLPGGalapagos0.2604 of 5 stars$28.09+1.3%$25.33-9.8%+13.1%$1.85B$288.19M0.001,310APGEApogee Therapeutics2.3868 of 5 stars$40.13-2.1%$94.60+135.7%+8.1%$1.85BN/A-16.5891Positive NewsGap DownBEAMBeam Therapeutics3.0763 of 5 stars$18.17-2.2%$48.75+168.3%-31.4%$1.83B$63.58M-10.32510Analyst RevisionGap UpIMCRImmunocore3.0496 of 5 stars$36.07-3.2%$58.89+63.3%-9.8%$1.81B$333.58M-37.97320Analyst UpgradeAnalyst RevisionHigh Trading VolumeTARSTarsus Pharmaceuticals1.9143 of 5 stars$43.11-1.8%$66.67+54.6%+32.0%$1.81B$233.67M-11.3150BHCBausch Health Companies3.9726 of 5 stars$4.88+2.5%$7.42+52.0%-4.8%$1.81B$9.73B-40.6619,900News CoveragePositive NewsInsider TradeGap Up Related Companies and Tools Related Companies IDEAYA Biosciences Alternatives Belite Bio Alternatives Schrödinger Alternatives Indivior Alternatives Galapagos Alternatives Apogee Therapeutics Alternatives Beam Therapeutics Alternatives Immunocore Alternatives Tarsus Pharmaceuticals Alternatives Bausch Health Companies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRML) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
